BioSpecifics Technologies Corp. (NASDAQ:BSTC) Director Jennifer M. Chao sold 3,313 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $60.74, for a total transaction of $201,231.62. Following the sale, the director now owns 6,000 shares in the company, valued at $364,440. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of BSTC opened at $56.51 on Tuesday. The company has a market cap of $431.02 million, a PE ratio of 21.75 and a beta of 1.30. BioSpecifics Technologies Corp. has a twelve month low of $40.58 and a twelve month high of $73.31.

BioSpecifics Technologies (NASDAQ:BSTC) last issued its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.02). The business had revenue of $8.13 million for the quarter, compared to the consensus estimate of $8.10 million. BioSpecifics Technologies had a return on equity of 21.08% and a net margin of 59.99%. On average, equities research analysts predict that BioSpecifics Technologies Corp. will post 3 earnings per share for the current fiscal year.

Several analysts have commented on BSTC shares. HC Wainwright set a $85.00 target price on shares of BioSpecifics Technologies and gave the stock a “buy” rating in a report on Tuesday, March 19th. Zacks Investment Research upgraded shares of BioSpecifics Technologies from a “hold” rating to a “buy” rating and set a $77.00 target price on the stock in a report on Tuesday, February 5th. Finally, BidaskClub downgraded shares of BioSpecifics Technologies from a “buy” rating to a “hold” rating in a report on Friday, March 29th.

Several institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC grew its stake in shares of BioSpecifics Technologies by 2.5% during the 4th quarter. Squarepoint Ops LLC now owns 7,950 shares of the biopharmaceutical company’s stock worth $482,000 after acquiring an additional 192 shares in the last quarter. Eagle Asset Management Inc. grew its stake in shares of BioSpecifics Technologies by 0.5% during the 1st quarter. Eagle Asset Management Inc. now owns 66,097 shares of the biopharmaceutical company’s stock worth $4,119,000 after acquiring an additional 329 shares in the last quarter. Northern Trust Corp grew its stake in shares of BioSpecifics Technologies by 0.4% during the 1st quarter. Northern Trust Corp now owns 92,931 shares of the biopharmaceutical company’s stock worth $5,792,000 after acquiring an additional 388 shares in the last quarter. Legal & General Group Plc grew its stake in shares of BioSpecifics Technologies by 50.1% during the 4th quarter. Legal & General Group Plc now owns 1,211 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 404 shares in the last quarter. Finally, Advantage Investment Management LLC bought a new position in shares of BioSpecifics Technologies during the 1st quarter worth approximately $42,000. 58.18% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Insider Selling: BioSpecifics Technologies Corp. (BSTC) Director Sells 3,313 Shares of Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.watchlistnews.com/insider-selling-biospecifics-technologies-corp-bstc-director-sells-3313-shares-of-stock/3030914.html.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.

Featured Story: What is the Quick Ratio?

Insider Buying and Selling by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.